Find your next paid study

GV20 TherapeuticsNCT05669430

~$150 – $4,200

Actual pay is set by the research site.

Locally Advanced or Metastatic Solid TumorsColorectal CancerGastric Cancer+1 more

An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with un…

ArriVent BioPharma, Inc.NCT07066657

~$150 – $4,200

Actual pay is set by the research site.

Gastric AdenocarcinomaGastric Cancer

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

This is a single-center, randomized, open-label clinical trial designed to evaluate the impact of low-dose olanzapine on weight loss, appetite, and nutritional…

University of Illinois at ChicagoNCT07581405

Actual pay is set by the research site.

Pancreas AdenocarcinomaBorderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma

Sequential Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

The objective of this research is to find out what effects (good and bad), the sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the…

Wake Forest University Health SciencesNCT05825066

Actual pay is set by the research site.

Pancreatic Ductal Adenocarcinoma (PDAC)

Intraperitoneal Paclitaxel With Standard Systemic NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis: Prospective Pilot Trial

This goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity)…

University of Colorado, DenverNCT07030283

~$150 – $3,000

Actual pay is set by the research site.

Hepatocellular CarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract Cancers+5 more

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and chang…

CancerFatigueBrain Tumor Adult

~$150 – $4,500

Actual pay is set by the research site.

AbbVieNCT06084481

Observational

Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention

The goal of this research study is to learn about the effects of the RISE-YA intervention on cancer-related fatigue in young adults who are brain cancer surviv…

M.D. Anderson Cancer CenterNCT07186556

~$10 – $750

Actual pay is set by the research site.

Registry of Myriad™ Utilization in Soft Tissue Reconstruction Procedures

This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll…

Abdominal Wound DehiscenceNecrotizing Soft Tissue InfectionLower Extremity Wound+4 more

Aroa Biosurgery LimitedNCT05243966

~$10 – $1,050

Actual pay is set by the research site.

High Grade Neuroendocrine Neoplasms

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in pa…

Washington University School of MedicineNCT06926634

Actual pay is set by the research site.

Observational

A Real-World, Single-Arm Observational Study Evaluating the Effects of MyVitalC (ESS60 in Extra Virgin Olive Oil) on Sleep Disturbance and Everyday Headaches

Sleep disturbance and recurring headaches can negatively affect daily functioning, mood, and productivity. MyVitalC (ESS60 in extra virgin olive oil) is a comm…

SleepHeadaches

~$10 – $1,050

Actual pay is set by the research site.

Efforia, IncNCT07477236

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called necti…

Solid Tumor, Adult

Corbus Pharmaceuticals Inc.NCT06265727

~$150 – $4,200

Actual pay is set by the research site.

Adamantinous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma

Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biolo…